Advances in molecular biology now make it possible to detect diseases sooner, allowing physicians to advise patients on optimal therapies. The Diagnostics and Personalized Medicine panel explores the changing world of diagnostics, bringing together executives, experienced venture capitalists, and a physician. Together they will explore the product areas and business models that have made diagnostics a hot area for investors today. Along the way, panelists will discuss new technologies of interest to consolidators and address the challenges start-ups face in commercializing these game-changing products.
Panelists include: Scott T. Garrett, Former Chairman and CEO of Beckman Coulter, Inc. Scott Garrett served as Chief Executive Officer at Beckman Coulter, Inc. from 2005 until September 2010. Previously, he was active in private equity investing and was the founder of Garrett Capital Advisors LLC. His prior experience includes leadership positions at Baxter International and American Hospital Supply Corporation, working in R&D, strategic planning, business development, and general management across a wide variety of businesses, including medical devices, clinical diagnostics, various healthcare services, and product distribution.
Peter Origenes, Vice President of Corporate Business Development at Becton Dickinson joined BD in 2004 after serving six years as a principal and then partner with a private venture capital firm, Radius Ventures, where he led or managed investments in biotechnology, specialty pharma and medical device companies. Peter holds Bachelor of Arts degrees in Genetics and History from the University of California at Berkeley, and a Master of Science in Industrial Administration from Carnegie Mellon University’s Graduate School of Industrial Administration (now the Tepper School of Business).
Risa Stack, MD, Partner at KPCB has 15 years of experience investing in personalized medicine, therapeutics, and platform technologies. Her investment career spans incubations to public companies. Most recently she has focused starting companies, often taking operational roles. Since joining Kleiner Perkins Caufield & Byers in 2003, Risa has worked to build and support KPCB’s personalized medicine portfolio and was named as one of the 100 Most Influential Women in Business by the San Francisco Business Times in 2004.
Katherine Kalin, Vice President of Franchise Strategic Management at Ortho Clinical Diagnostics is responsible for developing and implementing OCD’s global growth strategies through three coordinated functions: Worldwide & Strategic Marketing, New Business Development, and Global Business Insights. She has broad-based, global business experience as a result of leading three Johnson & Johnson medical device businesses, and a diverse range of healthcare consulting assignments, in the U.S., Europe and Asia.
The Diagnostics and Personalized Medicine panel will be moderated by James A. Datin, Executive Vice President and Managing Director of the Life Sciences Group, Safeguard Scientifics, Inc. Mr. Datin has more than 20 years of experience in business development, sales and marketing functions in diagnostic, device and healthcare covering assignments throughout the U.S., Europe and Asia. Mr. Datin has been a successful entrepreneurial CEO, raised capital for entrepreneurs to grow companies, and has turned around troubled companies. He joined Safeguard in September 2005 where he applies his broad industry knowledge to drive Safeguard’s capital deployment and partnership opportunities with molecular and point-of-care diagnostics, medical device, regenerative medicine and specialty pharmaceutical companies. Prior to Safeguard, Mr. Datin was CEO of Touchpoint Solutions; Group President of Dendrite International; Group Director, Corporate Business Strategy and Planning at GlaxoSmithKline; CEO of Isuta Holdings Berhad; and Director, International Business at Baxter/Merck KGaA.